Insider · CIK 0001675198
nancy lynn snyderman MD
director
Files at LYRA (Lyra Therapeutics, Inc.), ALKS (Alkermes plc.), AXNX (Axonics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 31, 2025 | ALKS Alkermes plc. | MOption exercise Ordinary Shares | +8,013 | - | - | 12,652 | Jun 2, 2025 |
| May 31, 2025 | ALKS Alkermes plc. | FTax withholding Ordinary Shares | -1,924 | $30.61 | $59k | 10,728 | Jun 2, 2025 |
| May 31, 2025 | ALKS Alkermes plc. | MOption exercise Restricted Stock Unit Awardderivative | -8,013 | - | - | 0 | Jun 2, 2025 |
| May 21, 2025 | ALKS Alkermes plc. | AGrant or award Non Qualified Stock Option (Right to Buy)derivative | +13,474 | $0.00 | $0 | 13,474 | May 23, 2025 |
| May 21, 2025 | ALKS Alkermes plc. | AGrant or award Restricted Stock Unit Awardderivative | +6,142 | $0.00 | $0 | 6,142 | May 23, 2025 |
| May 14, 2025 | LYRA Lyra Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +32,000 | $0.00 | $0 | 32,000 | May 16, 2025 |
| Nov 15, 2024 | AXNX Axonics, Inc. | DDisposition to issuer Common Stock | -14,944 | $71.00 | $1.1M | 0 | Nov 15, 2024 |
| Nov 15, 2024 | AXNX Axonics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,167 | $36.90 | $154k | 0 | Nov 15, 2024 |
| Nov 15, 2024 | AXNX Axonics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,000 | $49.96 | $500k | 0 | Nov 15, 2024 |
| Nov 7, 2024 | AXNX Axonics, Inc. | GGift Common Stock | -5,000 | $0.00 | $0 | 14,944 | Nov 12, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.